

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS  
USA, INC., and AKORN INC.<sup>1</sup>  
Petitioners

v.

SAINT REGIS MOHAWK TRIBE and ALLERGAN, INC.  
Patent Owners

---

Case IPR2016-01127 (8,685,930 B2)  
Case IPR2016-01128 (8,629,111 B2)  
Case IPR2016-01129 (8,642,556 B2)  
Case IPR2016-01130 (8,633,162 B2)  
Case IPR2016-01131 (8,648,048 B2)  
Case IPR2016-01132 (9,248,191 B2)

---

**PETITIONER TEVA PHARMACEUTICALS USA, INC.'S  
UPDATED MANDATORY NOTICES PURSUANT  
TO 37 C.F.R. § 42.8(a)(3)**

---

<sup>1</sup> Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Petitioner Teva Pharmaceuticals USA, Inc. (“Teva”) hereby files these Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8(a)(3) to update the listing of counsel and service information.

**I. LEAD AND BACK-UP COUNSEL**

Teva hereby adds Ralph Wilson Powers III (Reg. No. 63,504) as back-up counsel:

Ralph Wilson Powers III, Reg. No. 63,504  
[tpowers-PTAB@sternekessler.com](mailto:tpowers-PTAB@sternekessler.com)  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3932  
Tel.: 202-772-8876  
Fax: 202-371-2540.

All previously-listed counsel for Teva remain the same.

**II. SERVICE INFORMATION**

Teva consents to electronic service by email at the email addresses [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com), [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com), [IPRCyclosporine@carlsoncaspers.com](mailto:IPRCyclosporine@carlsoncaspers.com), [tpowers-PTAB@sternekessler.com](mailto:tpowers-PTAB@sternekessler.com), and [PTAB@sternekessler.com](mailto:PTAB@sternekessler.com).

Dated: December 26, 2018

Respectfully submitted,  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/ R. Wilson Powers III/

Ralph Wilson Powers III, Reg. No. 63,504  
Attorney for Petitioner Teva Pharmaceuticals USA,  
Inc.

## CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing **PETITIONER TEVA PHARMACEUTICALS USA, INC.'S UPDATED MANDATORY NOTICES PURSUANT TO 37 C.F.R. § 42.8(a)(3)** and Teva Pharmaceuticals USA, Inc.'s Updated Power of Attorney were served electronically via e-mail on December 26, 2018, in their entirety on the following counsel of record for Patent Owners:

Dorothy P. Whelan; Michael Kane; Susan Morrison Colletti; Robert M. Oakes;  
Jonathan Singer  
FISH & RICHARDSON P.C.  
[IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)  
[IPR13351-0008IP2@fr.com](mailto:IPR13351-0008IP2@fr.com)  
[IPR13351-0008IP3@fr.com](mailto:IPR13351-0008IP3@fr.com)  
[IPR13351-0008IP4@fr.com](mailto:IPR13351-0008IP4@fr.com)  
[IPR13351-0008IP5@fr.com](mailto:IPR13351-0008IP5@fr.com)  
[IPR13351-0008IP6@fr.com](mailto:IPR13351-0008IP6@fr.com)  
[PTABI inbound@fr.com](mailto:PTABI inbound@fr.com)

Alfonso Chan; Joseph DePumpo;  
Michael W. Shore;  
Christopher L. Evans  
SHORE CHAN DEPUMPO LLP  
[achan@shorechan.com](mailto:achan@shorechan.com)  
[jdepumpo@shorechan.com](mailto:jdepumpo@shorechan.com)  
[mshore@shorechan.com](mailto:mshore@shorechan.com)  
[cevans@shorechan.com](mailto:cevans@shorechan.com)  
  
Marsha K. Schmidt  
[marsha@mkschmidtlaw.com](mailto:marsha@mkschmidtlaw.com)

And on the counsel for Petitioners as follows:

Steven W. Parmelee; Michael T. Rosato;  
Jad A. Mills; Wendy L. Devine;  
Douglas H. Carsten  
WILSON SONSINI GOODRICH & ROSATI  
[sparmelee@wsgr.com](mailto:sparmelee@wsgr.com)  
[mrosato@wsgr.com](mailto:mrosato@wsgr.com)  
[jmills@wsgr.com](mailto:jmills@wsgr.com)  
[wdevine@wsgr.com](mailto:wdevine@wsgr.com)  
[dcarsten@wsgr.com](mailto:dcarsten@wsgr.com)  
Attorneys for Mylan Pharmaceuticals Inc.

Michael Dzwonczyk; Azadeh Kokabi;  
Travis Ribar  
SUGHRUE MION, PLLC  
[mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com)  
[akokabi@sughrue.com](mailto:akokabi@sughrue.com)  
[tribar@sughrue.com](mailto:tribar@sughrue.com)  
Attorneys for Akorn Inc.

Gary J. Speier; Mark D. Schuman  
CARLSON, CASPERS, VANDENBURGH,  
LINDQUIST & SCHUMAN, P.A.  
[gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com)  
[mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com)  
[IPRCyclosporine@carlsoncaspers.com](mailto:IPRCyclosporine@carlsoncaspers.com)  
Attorneys for Teva Pharmaceuticals  
USA, Inc.

Dated: December 26, 2018

Respectfully submitted,  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

/ R. Wilson Powers III/

Ralph Wilson Powers III, Reg. No. 63,504  
Attorney for Petitioner Teva Pharmaceuticals USA,  
Inc.